SCHEMBL3575209

SCHEMBL3575209

Cc1ccc(S(=O)(=O)OCCc2nc(-c3ccc(Oc4ccccc4)nc3)oc2C)cc1

nearest known ligand 0.45

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 19/20 0.45
PPARG P37231 18/20 0.45
PPARD Q03181 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4889024 0.88 PPARA (0.52) PPARAPPARGPPARD
Toluene SCHEMBL28752852 0.85 PPARA (0.43) PPARAPPARGPPARD
SCHEMBL4885359 0.84 PPARA (0.52) PPARAPPARGPPARD
SCHEMBL504044 0.84 PPARG (0.54) PPARAPPARGPPARD
SCHEMBL5124569 0.83 LMNA (0.51) PPARAPPARGPPARD
SCHEMBL4931991 0.82 PPARA (0.42) PPARAPPARGPPARD
SCHEMBL4894890 0.81 PPARA (0.43) PPARAPPARGPPARD
SCHEMBL4895428 0.81 PPARA (0.57) PPARAPPARGPPARD
SCHEMBL4893334 0.80 TP53 (0.52) PPARAPPARG
SCHEMBL4894698 0.79 PPARA (0.54) PPARAPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1989115-B Oxazole derivatives as histamine H3 receptor drugs and preparation and pharmaceutical use thereof LILLY CO ELI 2012-03-21 CN disclosed
US-7666871-B2 3-Methyl-6-(4-{5-methyl-4-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-oxazol-2-yl}-phenyl)-pyridazine; for treatment of obesity, cognitive deficiencies, narcolepsy ELI LILLY AND COMPANY (US) 2010-02-23 US disclosed
EP-1786790-B1 OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES LILLY CO ELI (US) 2009-06-03 EP disclosed
US-20070197604-A1 Oxazole derivatives as histamine h3 receptor agents,preparation and therapeutic uses ELI LILLY AND COMPANY 2007-08-23 US disclosed
EP-1786790-A1 OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2007-05-23 EP disclosed
WO-2006019833-A1 OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197604-A1 Oxazole derivatives as histamine h3 receptor agents,preparation and therapeutic uses HCRTR1, HRH3, HCRTR2 PPARA 1387/4885PPARG 1272/4885PPARD 1080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.